stockrow
Friday 6 November 2026
Export CNMD’s income statement to Excel — free account
CONMED Corporation
CNMD Healthcare Medical Devices
CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024.
- Revenue
- −0.70%
- EPS
- +635.0%
- Free cash flow
- −3.65%
- Total debt
- −4.44%
Quarter to September 2026, against a year earlier
51.50
1.33
−2.52%
Follow CNMD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
26.89 | 19.98 | 17.69 | 19.09 |
P/S ratio |
0.92 | 0.79 | 0.72 | 1.01 | |
P/FCF ratio |
8.35 | 8.74 | 7.32 | 10.43 | |
P/Operating CF |
27.19 | 80.28 | 26.53 | 28.00 | |
P/B ratio |
1.22 | 1.06 | 0.95 | 1.31 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.49 | 1.39 | 1.30 | 1.57 | |
EV/EBITDA |
11.25 | 9.91 | 9.33 | 9.96 | |
EV/Operating CF |
12.03 | 13.37 | 11.83 | 14.70 | |
EV/FCF |
13.61 | 15.42 | 13.25 | 16.21 | |
Quick Ratio |
0.92 | 0.90 | 0.61 | 0.61 | |
Current Ratio |
2.14 | 2.29 | 1.48 | 1.49 | |
Net Debt/EBITDA |
13.93 | 18.14 | 14.10 | 13.49 | |
Debt/Assets |
35.90% | 37.19% | 36.27% | 35.40% | |
Debt/Equity |
0.81 | 0.85 | 0.80 | 0.77 | |
Asset Turnover |
0.59 | 0.59 | 0.59 | 0.59 | |
Operating CF/Net income |
2.77 | 0.97 | 1.61 | 2.50 | |
Capex/Depreciation |
(0.25) | (0.14) | (0.15) | (0.14) | |
Interest Coverage |
4.97 | 3.60 | 4.62 | 3.34 | |
Research and Development Expense of Revenue |
3.99% | 5.15% | 4.51% | 4.65% | |
Selling, General and Administrative Expense of Revenue |
44.68% | 44.69% | 42.37% | 40.65% | |
Intangible Assets out of Total Assets |
0.60 | 0.60 | 0.59 | 0.59 | |
Share Based Compensation of Revenue |
1.33% | 1.74% | 1.52% | 1.76% | |
Graham Net Nets |
(0.49) | (0.58) | (0.59) | (0.41) | |
Graham Number |
33.63 | 36.40 | 37.97 | 43.93 | |
Earnings Yield |
3.72% | 5.01% | 5.65% | 5.24% | |
Free Cash Flow Yield |
11.97% | 11.44% | 13.66% | 9.59% | |
Revenue per Share |
12.02 | 10.37 | 11.42 | 11.21 | |
Operating CF per Share |
1.49 | 0.44 | 1.23 | 1.65 | |
Capex per Share |
(0.16) | (0.09) | (0.10) | (0.09) | |
Free Cash Flow per Share |
1.33 | 0.35 | 1.14 | 1.56 | |
Cash per Share |
1.32 | 1.15 | 1.24 | 1.60 | |
Shareholders Equity per Share |
33.29 | 33.27 | 34.63 | 35.42 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
33.29 | 33.27 | 34.63 | 35.42 | |
Free Cash Flow |
41.22 | 10.58 | 34.16 | 46.73 | |
Working Capital |
357.82 | 377.88 | 220.27 | 223.08 | |
Capital Expenditures |
(5.11) | (2.89) | (2.93) | (2.68) | |
Net Current Asset Value |
(619.79) | (626.68) | (583.25) | (562.50) | |
EV/EBIT |
20.02 | 17.02 | 16.14 | 15.87 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
12.28 | 9.65 | 8.92 | 10.20 | |
| Other line items | |||||
Average Receivables |
242.78 | 224.90 | 236.96 | 229.43 | |
Average Payables |
97.95 | 100.57 | 101.04 | 102.79 | |
Average Inventory |
351.13 | 360.39 | 361.22 | 363.59 | |
Average Assets |
2,316.00 | 2,306.31 | 2,314.38 | 2,313.48 | |
Average Common Equity |
997.89 | 997.65 | 1,022.13 | 1,034.09 |
Columns are period end dates · fundamentals updated 2 Nov 2026